Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533715 | 0.93 | HTR2C (0.52) | HTR2CHTR2ATP53HTR2B | |
| SCHEMBL10073890 | 0.88 | HTR2C (0.53) | HTR2CHTR2ATP53MAPT | |
| SCHEMBL10073212 | 0.77 | CYP1A2 (0.49) | HTR2CHTR2ATP53HTR2B | |
| SCHEMBL13533076 | 0.73 | HTR2C (0.54) | HTR2CHTR2AHTR2B | |
| SCHEMBL4940025 | 0.72 | HTR2C (0.48) | HTR2CHTR2AHTR2B | |
| SCHEMBL21646421 | 0.72 | TP53 (0.51) | TP53MAPT | |
| SCHEMBL10074089 | 0.71 | CYP1A2 (0.46) | HTR2CHTR2ATP53HTR2B | |
| SCHEMBL10073693 | 0.70 | HTR2C (0.45) | HTR2CHTR2ATP53 | |
| SCHEMBL10072963 | 0.70 | BCL2A1 (0.52) | HTR2CHTR2ATP53MAPT | |
| SCHEMBL22984921 | 0.69 | KDM4E (0.67) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310395-B1 | 9-SUBSTITUTED-B-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2012-01-18 | — | — | EP | disclosed |
| US-8071590-B2 | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2011-12-06 | — | — | US | disclosed |
| WO-2010004394-A1 | 9-SUBSTITUTED-B-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | WO | disclosed |
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | Q6ZSR9, NQO2, RECQL | HTR2C 3559/4885HTR2A 4321/4885TP53 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.